A Clinical Study on the Safety and Effectiveness of Donor Derived CD19 CAR-T Cells in the Treatment of R/R B-cell Acute Lymphoblastic Leukemia
The clinical trial is sponsored by Zhejiang University and aims to evaluate the safety and effectiveness of donor-derived CD19 CAR-T cells in treating relapsed or refractory B-cell acute lymphoblastic leukemia (R/R B-ALL). Given the increasing prevalence of R/R B-ALL and the growing demand for innovative therapies, this trial positions itself in a competitive landscape dominated by established CAR-T therapies such as Kymriah (Novartis) and Yescarta (Gilead). The trial's focus on donor-derived cells may offer a novel approach that could address limitations associated with autologous CAR-T therapies, such as preparation failures and patient eligibility. Successful outcomes could enhance market positioning and attract potential partnerships or acquisitions, particularly from companies looking to expand their oncology portfolios.
Indication: B-cell Acute Lymphoblastic Leukemia
Modality: protein therapy
Target: CD19 (Chimeric Antigen Receptor T-cell therapy)
Sponsor: Zhejiang University
Source URL: ClinicalTrials.gov
Source updated: Detailed source ingestion pending
Ingested: Jun 23, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by target_normalized: CD19 (Chimeric Antigen Receptor T-cell therapy)
View original source fields
Condition raw: B-cell Acute Lymphoblastic Leukemia
Condition normalized: B-cell Acute Lymphoblastic Leukemia
Modality raw: protein therapy
Modality normalized: protein therapy
Target raw: CD19 (Chimeric Antigen Receptor T-cell therapy)
Target normalized: CD19 (Chimeric Antigen Receptor T-cell therapy)